Nanobiotix’s NBTXR3 meets in Phase II/III for STS

Nanobiotix S.A. (Euronext:NANO) said NBTXR3 (PEP503) met the primary and secondary endpoints in the Phase II/III act.in.sarc trial to treat locally advanced soft tissue sarcoma. The compound comprises crystalline nanoparticles of hafnium

Read the full 327 word article

User Sign In